Osteoporosis | Pharmacor | G7 | 2015
Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in the osteoporosis market for therapies that are safer and more efficacious, particularly in reducing the risk of nonvertebral fractures (e.g., hip fractures). The launch of several key new therapies, coupled with changes in treatment guidelines and in physician prescribing behavior, will lead to significant market changes over the 2014-2024 forecast period. The osteoporosis and osteopenia market is maturing, but launches of novel agents including Merck’s odanacatib, Amgen/UCB’s romosozumab, and Radius’s abaloparatide, with both SC and TD routes of administration, will help to energize these markets.
